Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Enzon Commences Phase II Trial Of PEG-SN38
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer.
generic viagra online
International Symposium On Atherosclerosis Highlights Latest Treatment Advancements
Atherosclerosis, or hardening of the arteries with plaque buildup, is the underlying cause of heart disease and stroke, which together account for more than half of all death and disability in developed nations. The world"s largest forum for new research on the topic, the International Symposium on Atherosclerosis (ISA), will hold its 15th triennial meeting at the John B. Hynes Veterans Memorial Convention Center in Boston, June 14 to 18.
News of the day
New Research Evaluates The Impact Of Working Memory Training And Stimulant Medication On Kids With ADHD
A study to be published in the August 2009 edition of Applied Cognitive Psychology sheds new light on how Cogmed Working Memory Training and stimulant medication address working memory impairments in children with ADHD. Working memory, acknowledged as one of the core deficits in ADHD, represents the brain"s ability to hold and process critical information related to the present moment. This study represents the latest findings from a team of independent UK researchers whose ongoing work examines the impact of Cogmed"s software-based training program on individuals with disorders of memory and attention.
Public Health

Henry Ford Hospital Study May Hold Promise For Future Disease Therapies

Linking genetic material microRNAs with cells that regulate the immune system could one day lead to new therapies for treating cancer, infections and autoimmune diseases, according to a Henry Ford Hospital study. Qing-Sheng Mi, M.D., Ph.D., the study"s senior author and director of Henry Ford"s Immunology Program, says their findings are important because it shows for the first time an association between microRNAs and a key subset of immune regulatory cells in the body, natural killer T cells (NKT), which are known to lead to autoimmune diseases and cancer. The study was published June 1 in the Proceedings of the National Academy of Sciences. "While further studies are needed, we believe this provides important insight about how microRNAs can regulate NKT cells, and signals a major step forward in biology science for looking at new therapies for treating some chronic immune disease," Dr. Mi says. MicroRNAs are short strands of genetic material that researchers believe perform a vital role in healthy development by turning off gene activity. NKT cells potent regulators of diverse immune responses in the body. By genetically modifying mice with specific deletion microRNAs in hematopoietic stem cells, Henry Ford researchers showed that the lack of microRNAs can block the development and function of normal NKT cells. If researchers are successful at identifying unique microRNA that specifically regulate NKT cells, Dr. Mi, it could lead to new treatment therapies for some chronic disease. David Olejarz Henry Ford Health System


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009